• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- National Association of Corporate Directors/

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $BIIB alert in real time by email

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows:

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence

    WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately.

    The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape.

    Mantas serves on the boards of Biogen (NASDAQ:BIIB), where he chairs the compensation and management development committee, and International Flavors & Fragrances (NYSE:IFF), where he is on the innovation and audit committees. He is a Senior Advisor for NASDAQ, the Council for Global Competition and Innovation and IE University New York College and is vice chair of the board of HITEC. Mantas recently retired as the global leader of IBM Business Transformation Services.

    "I am honored to follow my mentor and fellow IBM senior leader Nick Donofrio as I join the NACD board," Mantas said. "As directors, we face compounding geopolitical, generational and technological disruption in the companies and communities we serve. I look forward to working with the NACD board and the broader corporate governance ecosystem to steward sustainable value creation in the global boardrooms we serve."

    Bricker brings together the combined impact of 134,000 Assurance partners and staff across the PwC network. He helps guide the development of trust, transparency and value creation for companies and investors through innovative, high-quality assurance solutions. Previously, he served as PwC U.S. vice chair and Trust Solutions co-leader, leading the firm's audit, digital assurance and tax reporting practices. Earlier, Bricker was chief accountant of the U.S. Securities and Exchange Commission. He also serves on the board of the American Institute of Certified Professional Accountants (AICPA) and as chair of the board of XBRL International.

    "NACD plays a critical role in elevating board performance and advancing trust in the capital markets," Bricker said. "I'm honored to join the NACD board and contribute to its work in strengthening governance, transparency and board-management alignment."

    Peter Gleason, president and CEO of NACD, welcomed both leaders to the board.

    "Jesús and Wes each bring exceptional insight and experience that reflect the dynamic needs of today's boards," Gleason said. "Jesús' expertise in digital transformation and innovation, combined with Wes' deep understanding of regulatory, legal and audit issues, will be invaluable as NACD continues to equip boards to lead with purpose and confidence."

    Mantas holds degrees in telecommunications and business administration from the Universidad Politécnica de Madrid and has served as an adjunct professor at the University of California Graduate School of Management and is certified in Corporate Governance by Harvard Business School. Bricker is a certified public accountant licensed in Virginia, Pennsylvania, New Jersey and the District of Columbia, and is a member of the New York State Bar Association.

    Visit the NACD Governance web page to learn more. 

    About NACD

    The National Association of Corporate Directors® (NACD®) is the leading member organization for corporate directors who want to expand their knowledge, grow their network and maximize their potential. For more than 47 years, NACD has helped boards and the business community elevate their performance and create long-term value. Our leadership continues to raise standards of excellence and advance board effectiveness at thousands of member companies.

    NACD's value insights, professional development events and resources, such as the NACD Directors Summit™ and the NACD Directorship Certification® program, support boards in navigating complex challenges. With a growing network of more than 24,000 members across more than 20 Chapters, boards are better equipped to make well-informed decisions on the critical, strategic issues facing their businesses today. Learn more at www.nacdonline.org.

    Press Contact: 

    Shannon Bernauer 

    sbernauer@nacdonline.org

    571-367-3688

    (PRNewsfoto/National Association of Corporate Directors)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/global-leaders-jesus-mantas-and-wes-bricker-join-nacd-board-of-directors-302580855.html

    SOURCE National Association of Corporate Directors

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $IFF

    CompanyDatePrice TargetRatingAnalyst
    Biogen Inc.
    $BIIB
    5/15/2026Outperform
    Evercore ISI
    Biogen Inc.
    $BIIB
    4/22/2026$225.00Neutral → Buy
    UBS
    Biogen Inc.
    $BIIB
    4/20/2026$250.00Equal Weight → Overweight
    Wells Fargo
    Biogen Inc.
    $BIIB
    4/14/2026$214.00Neutral → Overweight
    Piper Sandler
    Biogen Inc.
    $BIIB
    2/20/2026$185.00Equal Weight
    Barclays
    International Flavors & Fragrances Inc.
    $IFF
    2/13/2026$97.00Perform → Outperform
    Oppenheimer
    Biogen Inc.
    $BIIB
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    Biogen Inc.
    $BIIB
    1/7/2026$185.00Neutral
    UBS
    More analyst ratings

    $BIIB
    $IFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $20,317,854 worth of shares (273,500 units at $74.29), increasing direct ownership by 46% to 43,150 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    6/2/26 5:22:26 PM ET
    $IFF
    Major Chemicals
    Industrials

    President, Scent Teles De Mendonca Ana Paula converted options into 708 shares and covered exercise/tax liability with 362 shares, increasing direct ownership by 6% to 5,718 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    5/6/26 4:18:06 PM ET
    $IFF
    Major Chemicals
    Industrials

    EVP, Global Operations Officer Finzel Ralf converted options into 1,326 shares and covered exercise/tax liability with 734 shares, increasing direct ownership by 3% to 17,621 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    5/6/26 4:18:02 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

    Data presentations across multiple kidney diseases illustrate the breadth of Biogen's nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC). "Our presence across two key medical congresses highlights the momentum of our newly broadened nephrology portfolio, which

    6/3/26 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

    Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M

    6/1/26 1:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZURZUVAE issued to BIOGEN INC

    Submission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling

    4/23/26 6:14:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    SEC Filings

    View All

    SEC Form 8-K filed by International Flavors & Fragrances Inc.

    8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    6/1/26 9:00:02 AM ET
    $IFF
    Major Chemicals
    Industrials

    Biogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIOGEN INC. (0000875045) (Filer)

    5/14/26 8:31:16 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.

    SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)

    5/6/26 11:00:55 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $20,317,854 worth of shares (273,500 units at $74.29), increasing direct ownership by 46% to 43,150 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    6/2/26 5:22:26 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director Fribourg Paul J bought $10,971,329 worth of shares (156,459 units at $70.12) and sold $14,481 worth of shares (222 units at $65.23), increasing direct ownership by 92% to 29,650 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $995,204 worth of shares (14,260 units at $69.79), increasing direct ownership by 18% to 91,630 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:47 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Biogen

    Evercore ISI resumed coverage of Biogen with a rating of Outperform

    5/15/26 8:16:23 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by UBS with a new price target

    UBS upgraded Biogen from Neutral to Buy and set a new price target of $225.00

    4/22/26 7:42:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Biogen from Equal Weight to Overweight and set a new price target of $250.00

    4/20/26 8:20:15 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Leadership Updates

    Live Leadership Updates

    View All

    Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

    NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE:BFAM) will replace Tri Pointe Homes Inc. (NYSE:TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take

    5/7/26 6:01:00 PM ET
    $APLS
    $BFAM
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Consumer Discretionary

    Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent

    Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development With leadership experience at Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ:BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR) and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her know

    5/5/26 6:37:00 AM ET
    $BIIB
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    $IFF
    Financials

    Live finance-specific insights

    View All

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

    Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M

    6/1/26 1:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Completes Acquisition of Apellis Pharmaceuticals

    CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen. The acquisition adds two best-in-class commercialized products, EMPAVELI® and SYFOVRE®, significantly bolstering Biogen's near-term growth outlook and accelerating the Company's expansion into nephrology. Together, the products recorded $689 million in net product revenue in 2025. This transaction will strengthen Biogen's revenue and EPS growth potential by being accretive to Bioge

    5/14/26 8:35:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BIIB
    $IFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care